HLS Therapeutics Inc. has seen a decline in its stock price this week amid mixed news and low trading volume.
HLS Therapeutics Inc. (HLS.TO) has had a tough week, with its stock price dropping 3.72%. The latest close was C$4.25, reflecting a 2.13% decrease from the previous day. Despite some recent developments in the company, the stock hasn’t attracted much market attention.
Investor takeaway: Investors should pay attention to recent performance trends and company updates, especially the approval of NILEMDO® in Canada and the recent Q1 earnings report, as these could impact future stock performance.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$128.85M
52W high
$5.76
52W low
$4.00
1W change
-3.06%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 76.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.29
+76.9% Upside
Current Price
C$4.12
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
27.8%
Annualized
90-Day Vol
22.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.45
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.88 | C$3.53 – C$4.27 |
| 60 trading days | C$3.66 | C$3.19 – C$4.19 |
| 90 trading days | C$3.45 | C$2.92 – C$4.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
HLS Therapeutics Inc. Hits C$4.25, Down 3.72% This Week
With a market cap of about C$132 million, HLS Therapeutics continues to struggle with profitability, shown by a negative profit margin of 18.5%.
Bull case
The approval of NILEMDO® for reducing LDL cholesterol is a significant addition to HLS Therapeutics' product lineup. This could lead to revenue growth in the upcoming quarters.
Bear case
The stock's decline, along with low trading volume and negative profit margins, raises concerns about the company's ability to attract investor interest and maintain momentum in the market.
Recent Price Action
HLS Therapeutics Inc. closed at C$4.25 on Wednesday, down 2.13% for the day and 3.72% over the week. The stock has faced downward pressure, contributing to a year-to-date decline of 14.64%. This recent price action shows a lack of momentum, with limited trading activity.
Company Developments
Advertisement
Despite the stock's struggles, HLS Therapeutics has made progress in its operations. The company recently reported Q1 earnings of $12.9 million, a 2% increase year-over-year. Additionally, HLS received Health Canada approval for NILEMDO®, which could strengthen its product portfolio in the competitive healthcare market. However, these advancements have not yet sparked significant investor interest.
Technical Picture
The technical indicators for HLS Therapeutics show a current price of C$4.25, below the 50-day moving average of C$4.47 and the 200-day moving average of C$4.75, indicating bearish momentum. The stock has a 52-week range of C$4.00 to C$5.76, with only 14% of this range utilized. The low trading volume of 100 shares compared to the 20-day average of 30,479 shares suggests a lack of market interest.
Insider Activity
There have been no significant insider transactions reported recently for HLS Therapeutics, indicating that insiders may not be actively buying or selling shares at this time.
Price Action Summary
As of the last close, HLS Therapeutics Inc. is trading at C$4.25, down 2.13% for the day. Investors should keep an eye on upcoming developments and market conditions that could influence the stock's trajectory.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
